ArticleCancer immunology, immunotherapy : CII2009
Interferon regulatory factor 8 mediates tumor-induced inhibition of antigen processing and presentation by dendritic cells.
Article in Cancer immunology, immunotherapy : CII, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- NRGN inhibits CD8⁺ T cell effector function by downregulating MHC-I expression through the FMR1-IRF8 axis in hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2026Article
- TRIM63/IRF-8 axis promotes tumor progression and immunosuppression of melanoma with BRAF mutation.Cell death & disease · 2025Article
- Direct immunoactivation by chemotherapeutic drugs in cancer treatment.Advanced therapeutics · 2023Article
- Review
- Molecular patterns of cancer colonisation in lymph nodes of breast cancer patients.Breast cancer research : BCR · 2018Review
- High Antigen Processing Machinery component expression in Langerhans cells from melanoma patients' sentinel lymph nodes.Cellular immunology · 2017Article
- Downregulation of expression of transporters associated with antigen processing 1 and 2 and human leukocyte antigen I and its effect on immunity in nasopharyngeal carcinoma patients.Molecular and clinical oncology · 2014Article
- The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.Frontiers in immunology · 2013Review
- Altered local and systemic immune profiles underlie lymph node metastasis in breast cancer patients.International journal of cancer · 2013Article
- Regulatory dendritic cells in the tumor immunoenvironment.Cancer immunology, immunotherapy : CII · 2012Review
- [Paclitaxel blocks immunologic escape through up-regulating TAP-1, TAP-2 and eliminatiing Treg cells in 3LL-bearing mice].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2010Article
- Transcriptome analysis of porcine PBMCs after in vitro stimulation by LPS or PMA/ionomycin using an expression array targeting the pig immune response.BMC genomics · 2010Article
- Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
introductionSuppression of dendritic cells (DCs) is a crucial mechanism by which tumor cells escape immune recognition and elimination. We have recently reported that MHC class I antigen processing machinery (APM) component expression in human DCs is down-regulated by tumor-derived gangliosides. However, the molecular mechanisms underlying this abnormality were not identified. Thus, the aim of this work was to analyze the role of interferon regulatory factor 8 (IRF-8) in APM protein expression and the antigen presenting capacity of DCs developed in the tumor microenvironment.
resultsWe demonstrate that the expression of several MHC class I APM components, including delta, MB-1, LMP-10, ERp57, and tapasin, is significantly decreased in murine DCs generated in the presence of prostate cancer cells. APM component down-regulation was associated with decreased ability of DCs to present model antigen to antigen-specific T cells. Notable, impaired antigen-presenting activity of DCs co-cultured with tumor cells was accompanied by decreased levels of IRF-8. Transduction of DCs with the silencing RNA for the IRF-8 gene also led to reduced expression of APM components in DCs and decreased antigen presenting function.
conclusionTogether, our data suggest that tumor-induced inhibition of antigen processing and presenting function of DCs is mediated by IRF-8, a member of the interferon regulatory factor family. These results provide a new molecular target for optimizing the generation of efficient DC vaccines for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.